. home.aspx

NEWS

home.aspx
   


Precision Therapeutics’ Subsidiary, to Study Innovative Personalized Medicine Opportunities for Cancer Patients

April 11, 2019 / Precision Therapeutics Inc.

PITTSBURGH, April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly-owned subsidiary, Helomics® Corporation (Helomics), which provides personalized medicine solutions and boutique CRO services for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SpeciCare, an innovative Georgia-based company connecting cancer patients to new treatment options only available through storing the patient’s live tumor tissue, have signed an agreement for Helomics to provide CRO services and its D-CHIP artificial intelligence (AI) platform for a functional precision medicine study sponsored by SpeciCare. “SpeciCare is at the forefront of a renewed interest in functional precision medicine, which has been core to our personalized oncology approach for many years. We are excited to work with SpeciCare on their PIONEER initiative study, which will utilize Helo...